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Tumor-Derived Fibronectin Is Involved in Melanoma
Cell Invasion and Regulated by V600E B-Raf Signaling
Pathway
Ce´dric Gaggioli1, Guillaume Robert1, Corine Bertolotto1, Olivier Bailet1, Patricia Abbe1, Anne Spadafora1,
Philippe Bahadoran1, Jean-Paul Ortonne1, Ve´ronique Baron2, Robert Ballotti1 and Sophie Tartare-Deckert1
Melanomas are malignant tumors of melanocytes that, if not detected early, are highly aggressive and poorly
treatable. Activation of extracellular signal-regulated (ERK)/mitogen-activated protein (MAP) kinase signaling is
commonly found in melanomas mainly through oncogenic mutations of B-Raf. We previously reported that
activation of ERK/MAP kinase stimulates synthesis of fibronectin by upregulating the transcription factor early
growth response-1 (Egr-1). To further analyze the link between ERK/MAP kinase pathway and fibronectin in
melanoma, we have studied the regulation and role of fibronectin produced by melanoma cells bearing
oncogenic B-Raf mutation. We show that fibronectin is expressed in situ during tumor progression and that
high fibronectin and Egr-1 levels are found in cells expressing this mutation. Expression of active mutants of
B-Raf induces fibronectin, whereas endogenous fibronectin is inhibited by small interfering RNA (siRNA)-
mediated depletion of B-Raf or Egr-1. In contrast, stimulation of ERK pathway is insufficient to promote
fibronectin upregulation in normal melanocytes. Finally, we show that suppression of fibronectin by siRNA
leads to decreased melanoma cell invasiveness in vitro. These results reveal a tumor-specific regulation of
fibronectin by constitutive ERK/MAP kinase signaling and indicate that self-production of fibronectin may play a
role in melanoma tumorigenesis, by promoting tumor cell invasion.
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INTRODUCTION
Melanoma is a highly aggressive form of skin cancers that
may progress to a deadly metastatic disease. Its incidence has
been increasing worldwide over the past two decades.
Although primary tumors can be successfully surgically
removed, there is no satisfactory treatment for metastatic
melanoma (Houghton and Polsky, 2002). Melanomas arise
from malignant transformation of normal epidermal melano-
cytes (Goding, 2000; Herlyn et al., 2000). Typically, primary
lesions progress to malignant tumors through a multistep
process including dysplasia, radial growth phase (RGP),
invasive vertical growth phase (VGP), and metastasis. This
transition is accomplished through the accumulation of
genetic alterations in growth control pathways as well as
molecular changes in cell–cell and cell–matrix interactions
(Bogenrieder and Herlyn, 2002; Li et al., 2002). Despite
recent advances in the identification of genetic alterations
involved in oncogenic transformation of melanocytes, the
molecular mechanisms underlying the development and
progression of melanoma are still poorly understood (Polsky
and Cordon-Cardo, 2003).
Accumulating evidence point to the critical role of the Ras/
Raf/MEK (mitogen-activated protein (MAP) kinase kinase)/
ERK (extracellular signal-regulated kinase) MAP kinase path-
way in melanoma development. Abnormal activation of this
pathway occurs in melanoma because of oncogenic muta-
tions in BRAF and NRAS genes or through autocrine growth
factor stimulation (van Elsas et al., 1996; Brose et al., 2002;
Cohen et al., 2002; Davies et al., 2002; Pollock et al., 2003;
Satyamoorthy et al., 2003). Approximately, 60% of human
melanomas have mutational activation of the BRAF gene
(Davies et al., 2002). Mutations of the NRAS gene has also
been reported but with a lower frequency (van Elsas et al.,
1996). B-Raf is an immediate downstream mediator of Ras
signaling that belongs to the Raf family of serine/threonine
kinases. Once activated, Raf proteins stimulate a signaling
cascade involving MEK and MAP kinases, ERK1 and ERK2,
that ultimately regulates the activity of key transcription
factors leading to the control of cell growth, differentiation,
and survival (Hagemann and Rapp, 1999; Peyssonnaux and
Eychene, 2001). The V600E single substitution within the
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activation loop in exon 15 of BRAF accounts for 90% of
reported mutations and results in a constitutively active
kinase (Davies et al., 2002). V600E B-Raf leads to constitutive
ERK activity, increased in vitro colony formation, and
transformation of immortalized mouse melanocytes, whereas
suppression of V600E B-Raf expression has been reported to
cause inhibition of melanoma cells proliferation and survival
in vitro and in vivo (Davies et al., 2002; Calipel et al., 2003;
Hingorani et al., 2003; Karasarides et al., 2004; Sumimoto
et al., 2004; Wellbrock et al., 2004). Thus, oncogenic V600E
B-Raf-associated signaling pathway may support melanoma
growth and survival. Identification of downstream events
resulting from mutation of B-Raf is therefore a key issue to our
understanding of melanoma biology.
Adhesive interactions between tumor cells and the
extracellular matrix (ECM) regulate signaling events that
promote cell adhesion, migration, growth, and survival.
These interactions occur at multiple stages of metastasis
(Fidler, 1996). Cellular adhesion is primarily mediated by
integrins, a family of cell adhesion receptors, which provide
both the connection to the adhesive substrate and signaling to
the actin cytoskeleton (Giancotti and Ruoslahti, 1999).
Alterations in expression of adhesion molecules such as
integrins, MelCAM, cadherins, and cell surface proteoglycans
have been well documented in the development of malignant
melanoma (Bogenrieder and Herlyn, 2002; Li et al., 2002).
Abnormal expression of the fibronectin matrix protein has
also been linked to metastatic melanoma progression.
Fibronectin is one of the most important integrin ligand of
ECM, which controls many fundamental biological processes
(Hynes and Yamada, 1982). There is strong evidence that
expression of fibronectin is tightly correlated with the
acquisition of invasive and metastatic behavior of melanoma
cells (Bittner et al., 2000; Clark et al., 2000; Hoek et al.,
2004; Gaggioli et al., 2005). Besides melanoma, fibronectin
is also expressed in several other tumor cell types including
colorectal carcinomas, esophageal squamous cell carcino-
mas, papillary thyroid carcinomas, and breast carcinomas
(Zhang et al., 1997; Huang et al., 2001; Jiang et al., 2002;
Zhang et al., 2005). Importantly, blockade of fibronectin
binding to melanoma cells by synthetic peptides prevented
melanoma metastasis in mice (Humphries et al., 1986). These
observations support the hypothesis that during melanoma
development, overexpression of fibronectin can influence the
control and progression of metastasis by mediating integrin-
associated signaling pathways.
The biochemical mechanisms that control upregulation of
fibronectin in melanoma cells are beginning to unfold. We
recently observed that, stimulation of ERK/MAP kinase
signaling pathway by the hepatocyte growth factor (HGF)
induced fibronectin expression in melanoma cells through
upregulation and activation of the zinc finger transcription
factor early growth response-1 (Egr-1) (Gaggioli et al., 2005).
Because the deregulation of the ERK/MAP kinase pathway
arising from mutations in the BRAF gene occurs in most
melanomas, we sought to analyze the contribution of this
signaling pathway to fibronectin overexpression in melanoma
cells. We now show that fibronectin is a target gene of B-Raf
signaling in melanoma cell lines but not in normal
melanocytes, and that tumor-derived fibronectin may con-
tribute to melanoma tumorigenesis by promoting invasion of
cells that contain the B-Raf V600E mutation.
RESULTS
Fibronectin is expressed in situ during melanoma progression
We have shown previously that fibronectin protein is
expressed at much higher levels in human melanoma cell
lines compared to normal melanocytes (Gaggioli et al.,
2005). Also, increase of fibronectin mRNA was reported to be
associated with melanoma metastasis (Bittner et al., 2000;
Clark et al., 2000). In this study, we extended the analysis of
fibronectin expression to normal skin and melanoma samples
to determine whether the increase of fibronectin also occurs
in the tumor lesion itself. Immunofluorescent staining
analysis was performed on normal human foreskin and
primary melanomas biopsies (two RGPs and one VGP). In
normal skin, melanocytes were stained for tyrosinase related
protein (TRP)-1 to detect their location in the basal layer of
the epidermis (Figure 1). Fibronectin was strongly positive in
the dermis but virtually absent in epidermis. In melanoma
sections, the intensity level of fibronectin staining associated
with TRP-1-positive cells significantly increased compared
to normal epidermis. In primary VGP melanoma no. 3,
fibronectin staining tend to be uniform throughout the tumor,
whereas in RGP melanomas nos. 1 and 2 the intensity varied
in different areas of the tumor. This indicates that within a
lesion, melanoma cells were heterogeneous for fibronectin
expression and also that fibronectin immunostaining did not
correlate with TRP-1 expression in these melanomas. Inter-
estingly, in melanoma no. 1 lesion, cells appeared positive
for fibronectin in the deep portion of the tumor nest and
negative in the superficial portion. Finally, it may be worth
noting that fibronectin localized in punctuate pattern that
contrasted with the well-organized network of matrix
observed in the dermis. These results indicate that fibronectin
was expressed in primary melanomas and corroborate the
aberrant fibronectin protein expression pattern observed in
melanoma cell lines.
Overexpression of fibronectin and Egr-1 is associated with
oncogenic mutation of B-Raf in human melanoma cell lines
The zinc-finger transcription factor Egr-1 regulates fibronectin
gene expression via activation of the ERK/MAP kinase
pathway in human MeWo melanoma cells (Gaggioli et al.,
2005). This observation led us to examine the expression
profile of Egr-1 during melanoma progression and compare it
with that of fibronectin. Real-time PCR was first used to
evaluate fibronectin and Egr-1 mRNA levels in human
primary melanocytes and metastatic melanoma cell lines. In
agreement with our previous observation (Gaggioli et al.,
2005), cells expressing oncogenic B-Raf (A375, 1205Lu, and
SKmel28) showed high levels of fibronectin mRNA (Figure
2a, left panel). In contrast, in MeWo cells that express wild-
type B-Raf, fibronectin was expressed at a level comparable
with that of normal melanocytes. A similar expression pattern
was observed for Egr-1. Egr-1 mRNA was more abundant in
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the tumor cell lines having V600E mutation compared with
MeWo or normal melanocytes (Figure 2a, right panel).
Fibronectin and Egr-1 expression analysis was next extended
to melanoma cell lines derived from primary RGP and VGP
melanoma lesions. Total cell lysates from two RGP melano-
mas (WM35 and SBcl2), one VGP melanoma (WM793), and
four metastatic melanomas (MeWo, 501mel, 1205Lu, and
A375), together with melanocytes were analyzed by Western
blotting with antibodies against fibronectin and Egr-1. ERK
activities were also evaluated with an antibody specific for
the dually phosphorylated and activated MAP kinases, ERK1
and ERK2. Figure 2b shows that Egr-1 and fibronectin protein
levels were higher in WM35, WM793, 1205Lu, and A375
cells than in MeWo, 501mel, SBcl2, or normal melanocytes.
Relatively low levels of fibronectin and Egr-1 were seen in
501mel cells, which contain the V600E B-Raf mutation but
exhibited low level of activated ERK1/2. Note that in
comparison with melanocytes, we observed that under the
experimental conditions used, most of the wild-type B-Raf
melanoma cells exhibited significant phospho-ERK levels.
Immunoprecipitation using an Egr-1-specific antibody further
confirmed increased levels of Egr-1 in 1205Lu and A375 cells
compared to MeWo or 501mel cells (Figure 2c). These results
indicate that Egr-1 is expressed in melanoma cell lines that
harbor V600E B-Raf and increased ERK/MAP kinase activity,
suggesting that Egr-1 is a target of this pathway in these cells.
Moreover, the parallel expression pattern observed between
Egr-1 and fibronectin is consistent with the hypothesis that
Egr-1 modulates fibronectin expression in melanoma cells.
We next asked whether the increase in fibronectin
expression might allow melanoma cells to accumulate
fibronectin matrix on the cell surface. As expected, the
fibronectin matrix was barely detectable by immunofluores-
cence on MeWo cells whereas WM35 and 1205Lu cells
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Figure 1. Detection of fibronectin in normal skin and melanoma specimens by immunofluorescence analysis. Frozen sections were fixed and stained, as
indicated, for fibronectin (green), TRP-1 (red), and a control serum (data not shown). FITC-conjugated anti-rabbit and Texas Red-conjugated anti-rat secondary
antibodies were used. TRP-1 staining was used to identify melanocytic skin cells. Slides were examined with a Zeiss Axiophot fluorescence microscope and
pictures were taken at 20 magnification. Arrow shows a melanocyte that resides on the dermal–epidermal junction. Panels for merge images are shown.
Analysis of normal skin revealed strong fibronectin signals in dermis but no signal in epidermis. In melanoma sections, staining revealed a significant and
punctuate expression pattern associated with TRP-1 signals. E, epidermis; D, dermis; and T, nest of tumor cells. Melanoma specimen no. 1, RGP, tumor thickness
0.40 mm, Clark level II. Melanoma specimen no. 2, RGP, tumor thickness 0.55 mm, Clark level II. Melanoma specimen no. 3, VGP, tumor thickness 0.80 mm,
Clark level III.
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exhibited higher levels of the protein and displayed a
moderately, developed pericellular fibronectin network
(Figure 2d).
Fibronectin overexpression depends on ERK activity and
requires V600E B-Raf
The correlation between oncogenic B-Raf signaling and
fibronectin expression prompted us to examine the role of
MAP kinase and B-Raf in particular in fibronectin regulation.
We first examined the effect of B-Raf V600E expression on
fibronectin gene transcription. The ability of V600E mutant to
induce the fibronectin promoter was tested in MeWo cells,
which have low levels of ERK activity. When fibronectin–
luciferase construct was transfected along with increasing
amount of B-Raf V600E expression vector, a dose-dependent
induction in luciferase activity was observed, indicating
that activation of ERK/MAP kinase pathway by expression
of V600E B-Raf stimulates transcriptional activation of fibro-
nectin (Figure 3a). We next tested if activated B-Raf could
stimulate expression of endogenous fibronectin protein.
300
200
100
0
M
el
an
oc
yt
esF
n 
m
R
N
A 
ex
pr
es
sio
n
(ar
bit
ray
 un
its
)
300
400
200
100
0
Eg
r-1
 m
RN
A 
ex
pr
es
sio
n
(ar
bit
ray
 un
its
)
M
eW
o
A3
75
*
12
05
Lu
*
SK
m
el
28
*
M
el
an
oc
yt
es
Fi
br
on
ec
tin
N
uc
le
i
W
M
35
*
W
M
79
3*
M
eW
o
SB
cl2
A3
75
*
12
05
Lu
*
M
el
an
oc
yt
es
M
eW
o
A3
75
*
12
05
Lu
*
SK
m
el
28
*
M
eW
o
50
1m
el
*
50
1m
el
*
A3
75
*
12
05
Lu
*
*: B-Raf mutated melanoma cells
Blot:
Blot: Egr-1
IP: Egr-1
Egr-1
p-ERK1/2
ERK2
MeWo
RGP VGP Metastatic
WM35 1205Lu
ERK2 WCL
Fibronectin
*
b c
d
Figure 2. Fibronectin and Egr-1 are expressed at high levels in melanoma cells expressing V600E B-Raf. (a) Total RNA was isolated from primary melanocytes
and wild type B-Raf (MeWo) or V600E B-Raf (A375, 1205Lu, and SKmel28) melanoma cell lines. Real-time reverse transcription–PCR was performed and data
were normalized against four housekeeping genes as described in Materials and Methods. Fibronectin (Fn) and Egr-1 mRNA values were expressed as arbitrary
units and represent means7SD of triplicates and are representative of two independent experiments. (b) Whole-cell lysates were collected from primary
melanocytes or from the indicated primary or metastatic melanoma cell lines, separated on SDS–PAGE and analyzed by Western blotting using antibodies
against fibronectin, Egr-1, and phospho-ERK1/2. Antibody to ERK2 was used as loading control. *Non-specific band. Arrow points to Egr-1 protein.
(c) Whole-cell lysates (WCL) were immunoprecipitated with anti-Egr-1 followed by anti-Egr-1 blot (upper panel) or directly analyzed with anti-ERK2 blot as
loading control (lower panel). (d) Immunofluorescence staining of pericellular fibronectin on the surface of MeWo, WM35, and 1205Lu cells. Cells were fixed
and stained with anti-fibronectin antibody (green) or 4,6-diamidino-2-phenylindole (blue) to reveal nuclei. Cells were viewed under a fluorescence microscope
(Zeiss). Bar¼5 mm.
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Adenoviruses expressing active B-Raf (B-RafCAAX) or vector
control were administered to MeWo cells and infection was
controlled by detection of hemagglutinin-tagged B-Raf
protein in Western blot (data not shown). Figure 3b clearly
showed that expression of B-RafCAAX stimulated ERK1/2
activity and increased levels of fibronectin protein. In
addition, expression of B-RafCAAX resulted in an increase
of Egr-1 protein amount. The latter observation is consistent
with the possibility that B-Raf stimulates fibronectin expres-
sion via upregulation of Egr-1.
To further explore the role of constitutive ERK signaling
on the basal activity of the fibronectin promoter in melanoma
cells, we used the MEK inhibitor U0126 to inhibit
ERK activity in these cells. After transfection with the
fibronectin–luciferase construct, MeWo, 1205Lu, and A375
cells were treated with 10 mM of U0126 for 48 hours, and then
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Figure 3. Regulation of endogenous fibronectin and Egr-1 by oncogenic B-Raf in melanoma cells. (a) Transcriptional activation of the fibronectin promoter by
B-RafV600E. MeWo cells were transfected with the fibronectin promoter luciferase reporter (200 ng) and increasing amounts of a vector expressing V600E B-Raf
(from 10 to 200 ng). Luciferase activities were determined 48 hours post-transfection. Activities were normalized to b-galactosidase activities and expressed
as fold induction. (b) Expression of B-RafCAAX increases fibronectin and Egr-1 protein levels. MeWo cells were infected with either control or B-RafCAAX
adenovirus. Fibronectin and Egr-1 protein levels as well as ERK1/2 phosphorylation were assayed by Western blot 48 hours after infection. TfR is shown as a
loading control. (c) ERK/MAP kinase-dependent expression of fibronectin and Egr-1. Upper panel: MeWo, A375, and 1205Lu cells were transfected with
the fibronectin promoter luciferase reporter, cultured with 10 mM of the MEK inhibitor U0126 for 48 hours, and harvested for luciferase activity. Values were
normalized to b-galactosidase activities to eliminate differences in transfection efficiency. Insets show Western blot using anti-phospho ERK1/2 antibody of the
indicated cell lines after 48 hours treatment with U0126. Lower panel: Western blot with anti-fibronectin and anti-Egr-1 antibodies showing levels of fibronectin
and Egr-1 in control and U0126-treated 1205Lu cells. Total ERK2 is shown as a loading control. (d) siRNA against B-Raf downregulates fibronectin and
Egr-1 expression in 1205Lu cells. Cells were transfected with luc siRNA or B-Raf siRNA as indicated. After 72 hours, cell lysates were blotted for total B-Raf,
phospho-ERK1/2, total ERK2, Egr-1, and fibronectin as indicated. Results are representative of two independent experiments.
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luciferase assays were performed. As expected, treatment of
1205Lu and A375 cells with U0126 eliminated constitutive
phosphorylation of ERK1/2 (Figure 3c, upper panel). Com-
pared with MeWo, 1205Lu cells showed high levels of
fibronectin reporter activity that was abrogated by U0126
treatment. A similar ERK activity dependence was seen in
A375 cells. Significantly, inhibition of the ERK pathway also
reduced fibronectin and Egr-1 protein levels (Figure 3c, lower
panel). These results indicate that upregulation of fibronectin
and Egr-1 is a consequence of constitutive ERK/MAP kinase
signaling.
We also examined regulation of fibronectin expression via
small interfering RNA (siRNA)-mediated knockdown of
V600E B-Raf in 1205Lu melanoma cells. This siRNA
specifically depleted B-Raf but not c-Raf or ERK2, and led
to suppression of the constitutive ERK signaling (Figure 3d
and data not shown). Consistent with the results from U0126
treatment, we observed a significant reduction of fibronectin
and Egr-1 protein levels upon depletion of B-Raf. Similar
results were obtained in A375 melanoma cells (data not
shown). These findings suggest that V600E B-Raf contributes
to fibronectin and Egr-1 expression in 1205Lu melanoma
cells.
Egr-1 is required for fibronectin production in melanoma cells
Our findings obtained so far raise the possibility that Egr-1
might be responsible for increasing fibronectin in cells that
harbor V600E B-Raf. To test this, we infected 1205Lu cells
with an adenoviral vector expressing nerve growth factor-IA
binding protein (NAB2), a specific repressor of Egr-1 activity
(Svaren et al., 1996) (Figure 4a). Control cells were infected
with an adenoviral vector expressing green fluorescent
protein alone. After 48 hours, cells were analyzed for
fibronectin expression by Western blotting. Figure 4a shows
that expression of NAB2 inhibited the expression of
fibronectin, and as expected, Egr-1 protein levels were not
affected in cells infected with AdNAB2. This indicates that
inhibition of Egr-1 transcriptional activity results in reduced
fibronectin production. Next, we used siRNA to selectively
knockdown Egr-1 protein levels in 1205Lu cells. Cells
transfected with an Egr-1-specific siRNA showed significant
downregulation of Egr-1 but also a decrease in fibronectin
amount (Figure 4b). These results further suggest that Egr-1
contributes to fibronectin expression in these melanoma
cells.
Lack of fibronectin regulation by activated ERK in normal
melanocytes
To investigate whether the regulation of fibronectin by ERK
signaling is specific to malignant melanocytes, we analyzed
the expression of fibronectin in normal primary melanocytes
expressing activated B-Raf or after 2 days of treatment with
HGF, a potent inducer of the Ras/Raf/MEK/ERK pathway
(Figure 5). Adenoviral infections revealed that expression of
B-RafCAAX stimulated both ERK signaling and Egr-1 expres-
sion, but failed to increase fibronectin protein levels (Figure
5a). Similarly, no appreciable induction of fibronectin was
seen in melanocytes exposed to HGF, despite the stimulation
of ERK1/2 phosphorylation and upregulation of Egr-1 (Figure
5b). Similar results were obtained using melanocytes isolated
from several donors (data not shown). These observations
indicate that regulation of fibronectin expression by activated
ERK/MAP kinase signaling pathway is limited to transformed
melanocytes.
AdNAB2 Blot: luc Egr-1
siRNAAdenoviral infection
Blot:
Fibronectin Fibronectin
NAB2
Egr-1
Egr-1
ERK2
ERK2
a b
AdGFP
Figure 4. A role for Egr-1 in fibronectin expression in 1205Lu melanoma
cells. (a) Cells were infected with adenoviruses encoding green fluorescent
protein alone or NAB2 green fluorescent protein. NAB2, fibronectin, and
Egr-1 protein levels as well as ERK2 were assayed by Western blot 72 hours
after infection. (b) Cells were transfected with luc siRNA or Egr-1 siRNA as
indicated. After 72 hours, cell lysates were blotted for Egr-1 and fibronectin
as indicated. Results are representative of two independent experiments.
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Figure 5. Activation of ERK/MAP kinase signaling pathway does not regulate
fibronectin expression in normal melanocytes. (a) Expression of B-RafCAAX
induces sustained activation of ERK1/2 and promotes Egr-1 expression.
Human primary melanocytes were infected with either control or B-RafCAAX
adenovirus. Fibronectin and Egr-1 protein levels as well as ERK1/2
phosphorylation were assayed by Western blot 48 hours after infection. Total
ERK2 is shown as a loading control. (b) HGF stimulates ERK1/2 activation and
Egr-1 upregulation. Human primary melanocytes were serum-starved over-
night and then incubated with HGF (50 ng/ml) for the indicated times. Cell
lysates were blotted for Egr-1, phospho-ERK1/2, total ERK2, and fibronectin as
indicated. Notice that no change in fibronectin protein levels was observed.
Similar results were obtained with three independent melanocyte cultures.
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Tumor-derived fibronectin is involved in the invasive potential
of melanoma cells
To examine the biological consequences of fibronectin
production by melanoma cells, we designed an siRNA
sequence to target fibronectin in 1205Lu cells. As shown in
Figure 6a, Western blot analysis of whole-cell lysates 4 days
after transfection with fibronectin siRNA revealed more than
80% reduction in fibronectin protein level without any
significant modulation of the amount of ERK2 used as
control. Consequently, staining of pericellular fibronectin in
1205Lu transfected with the fibronectin siRNA was comple-
tely negative (Figure 6b). We first compared the adhesive
capacities of control and fibronectin siRNA-transfected cells
and found that fibronectin silencing decreases melanoma
cells anchorage to substratum and that fibronectin-depleted
cells were more sensitive to detachment after trypsinization
than control cells (data not shown). In subsequent experi-
ments, the invasion ability of fibronectin-silenced melanoma
cells was evaluated in Boyden chambers by using inserts
coated with ECMatrix. As shown in Figure 6c, the number
of cells that migrated through a reconstituted basement
membrane was significantly lower in fibronectin-depleted
cells than in control cells. These findings are consistent with
the possibility that production of fibronectin by melanoma
cells contributes to their invasive phenotype.
DISCUSSION
We have shown previously that fibronectin is overexpressed
in several melanoma cell lines that display constitutive ERK/
MAP kinase signaling, suggesting a role of this signaling
pathway in fibronectin regulation. We also reported that
HGF, a growth factor produced by melanoma cells, induces
fibronectin expression through ERK/MAP kinase-dependent
expression of Egr-1 (Gaggioli et al., 2005). Moreover, global
gene expression analyses have shown that an increase of
fibronectin mRNA accompanies oncogenic transformation of
melanocytes and correlates with acquisition of tumorigenic
and metastatic potentials (Bittner et al., 2000; Clark et al.,
2000; Hoek et al., 2004). Collectively, these studies support
the idea that self-production of fibronectin might contribute
to the invasive behavior of melanomas. This study was
designed to expand on these observations and to determine
the role of oncogenic B-Raf and ERK/MAP kinase in general,
on fibronectin regulation in melanoma cells. We first
confirmed that increase in fibronectin expression observed
in melanoma cell lines also occurs in the primary cancer
lesion itself. Here, we have analyzed a limited number of
melanomas and found for two lesions intratumoral differ-
ences in fibronectin staining that might reflect heterogeneity
in fibronectin expression pattern in tumor cells within the
same lesion. We are presently studying a large number of
human primary and metastatic melanomas as well as nevi by
immunohistochemistry in order to define with certainty the
pattern of fibronectin expression in melanomas and during
disease progression. Interestingly, the pattern of pericellular
fibronectin observed in melanomas is distinguishable from
the fibrillar network seen in dermis. This might be consistent
with a cleveage of fibronectin by tumor-derived proteolytic
enzymes such as matrix metalloproteases or tissue serine
proteinases. Melanoma cells are known to secrete high levels
of these ECM-degrading enzymes (Bogenrieder and Herlyn,
2002). Proteolysis of tumor-produced fibronectin will gen-
erate matrix fragments that might have beneficial effects on
migratory properties. In this regard, upregulation of fibro-
nectin may provide transformed melanocytes with a selective
advantage to escape the epidermis and invade the underlying
dermis. Alternatively, proteolysis of tumor-produced fibro-
nectin may serve as a reservoir for growth factors or cytokines
that will provide clues necessary for tumor growth and
survival. Finally, another attractive possibility is that produc-
tion of fibronectin may influence tumor implantation during
the metastatic process. This might be of importance for the
adaptation of tumor cells to local requirements. Studies are
under way to examine these different hypotheses. As one step
toward elucidation of the role of tumor-derived fibronectin in
melanoma cells behavior, we tested whether its invalidation
may affect adhesion and invasion of 1205Lu cells. We show
that blocking fibronectin expression with specific siRNA
partially inhibits invasive capabilities of these cells. This
finding adds weight to the idea that fibronectin may support
melanoma progression by promoting adhesion and invasion
of tumor cells.
Oncogenic mutations of B-Raf resulting in constitutive
activation of ERK/MAP kinase signaling pathway are a major
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Figure 6. Fibronectin silencing leads to decreased invasion capacity of
1205Lu melanoma cells. (a) Western blot analysis of cell lysates 96 hours after
transfection with siRNA against luciferase (luc) or against fibronectin (Fn). Cell
lysates were blotted with specific antibodies to fibronectin. Total ERK2 is
shown as a loading control. (b) Immunofluorescence of control and
fibronectin siRNA-transfected cells with antibodies directed to fibronectin
(green). Nuclei were stained with 4,6-diamidino-2-phenylindole (blue).
Bar¼25 mm. (c) Cells were transfected with luc siRNA or fibronectin siRNA,
starved overnight, detached, and then assayed for their ability to invade
ECMatrix using a modified Boyden chamber assay. Invasion was quantitated
by visual counting. Mean values of cell counts were obtained from five
individual fields. Similar results were obtained in two independent
experiments.
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characteristic of melanoma (Davies et al., 2002). Here, we
provide several lines of evidence that this signaling pathway
is required to maintain high fibronectin levels in melanoma
cells. Thus, the presence of these activating mutations in the
majority of melanoma may account for the overexpression of
fibronectin found in these cells compared to normal
melanocytes. Besides B-Raf mutations, more than 20%
melanoma harbor oncogenic mutations in the NRAS gene
occurring mainly in lesions from sun-exposed sites. BRAF and
NRAS mutations appear to be equivalent in the constitutive
activation of the MAP kinase signaling pathway and are
generally found with mutual exclusion in melanoma (Brose
et al., 2002; Davies et al., 2002; Pollock et al., 2003; Garnett
and Marais, 2004). Thus, it seems likely that fibronectin
through Egr-1 expression would be a target of MAP kinase
pathway in melanoma cells carrying activating mutations in
N-Ras. This view is supported by our previously reported
findings showing high fibronectin levels in N-Ras-mutated
melanoma cells (Gaggioli et al., 2005 and unpublished
observations). Further, our previous observation that fibro-
nectin can also be induced by activation of ERK/MAP kinase
pathway in response to HGF suggests that in some melano-
mas not bearing activating B-Raf or N-Ras mutations, fibro-
nectin may also be induced through autocrine growth factor
stimulation (Gaggioli et al., 2005). Altogether, these findings
support the idea that expression of fibronectin is a general
feature of melanoma cells.
Importantly, we have observed that oncogenic B-Raf
upregulates the expression of fibronectin, most likely through
Egr-1 transcriptional activity. These results are in agreement
with previous studies showing that fibronectin is a direct
Egr-1-responsive gene (Liu et al., 2000; Gaggioli et al., 2005).
Interestingly, we observed that Egr-1 levels are correlated
with fibronectin levels and with B-Raf-mediated ERK/MAP
kinase signaling. This observation further emphasizes the
involvement of Egr-1 in B-Raf-dependent fibronectin synth-
esis. To our knowledge, this is the first report showing an
increase of Egr-1 expression in melanoma cells compared to
normal melanocytes. The Egr-1 promoter contains several
serum response elements and Ets binding sites that mediate its
induction (Cohen et al., 1996; Thiel and Cibelli, 2002). These
elements are regulated by ternary complex factors, which
include Elk-1. Elk-1 is a direct target of the MAP kinase
pathway, and studies have shown that Elk-1 is continuously
phosphorylated and activated by upstream MAP kinases in
melanoma cells harboring B-Raf V600E mutation (Conner
et al., 2003; Satyamoorthy et al., 2003). Based on this, it
seems likely that Elk-1 may contribute to the transcriptional
regulation of Egr-1 and subsequent fibronectin gene expres-
sion in these cells. In support to this, we have observed that
expression of a dominant-negative mutant of Elk-1 inhibits
Egr-1 expression in V600E B-Raf-positive cells (data not
shown). As for fibronectin, we can predict that Egr-1 is
upregulated by constitutive activated ERK/MAP kinase path-
way in melanoma cells having oncogenic mutation of N-Ras.
Besides fibronectin, Egr-1 has been shown to regulate the
expression of the adhesion receptor CD44v6 in melanoma
cells (Recio and Merlino, 2003). Together with this report,
our study supports a potential role for Egr-1 in transcriptional
induction of molecules implicated in the interaction between
tumor cell and ECM. It will be interesting now to determine
whether selective inhibition of Egr-1 expression (by siRNA
knockdown) or activity (by NAB2 expression) modulates
melanoma cells adhesion, migration, and/or invasion.
Interestingly, we have found that activation of ERK/MAP
kinase signaling and expression of Egr-1 are not sufficient to
promote fibronectin expression in normal melanocytes. This
indicates that regulation of fibronectin by this signaling
pathway is limited to transformed cell lines and likely reflects
a tumor-specific regulation. Our findings suggest that in
contrast to transformed cells, melanocytes are not pro-
grammed to produce fibronectin following ERK activation.
Consistent with this, stimulation of Ras/B-Raf/ERK pathway by
the melanocyte-differentiating agent cAMP did not induce
fibronectin expression in normal melanocytes (unpublished
results). The mechanism of tumor-specific regulation of
fibronectin remains unclear, but could involve the regulation
of additional targets in melanoma cells. One attractive
candidate is the transcription factor Snail. Snail has been
shown to promote fibronectin expression in carcinoma cells
(Cano et al., 2000), and is expressed in several melanoma cell
lines but absent in melanocytes (Poser et al., 2001; Robert
et al., 2006). These suggest that Snail may contribute to
fibronectin regulation in melanoma cells. Alternatively, the
b-catenin-dependent signaling pathway could be involved in
this process as b-catenin signaling is activated in most
melanoma cells and known to control fibronectin expression
(Rubinfeld et al., 1997; Gradl et al., 1999). Another
possibility is that a putative repressor prevents fibronectin
transcription in melanocytes and that its expression will be
lost during oncogenic transformation. In this regard, NAB
proteins (NAB1 and NAB2) might be potential candidates for
such repression by blocking Egr-1-dependent transcription
(Russo et al., 1995; Svaren et al., 1996). However, it seems
unlikely because we did not observe, in preliminary
experiments, the modulation of NAB1 and NAB2 levels
between normal melanocytes and melanoma cells (unpub-
lished observations). Because changes in DNA methylation
often occur during tumor development, we can also
hypothesize that activity of the fibronectin promoter is
subject of epigenetic inactivation in normal melanocytes.
Interestingly, methylation is observed in the CpG islands of
promoter regions and these sequences often match with Egr-
1-binding sites (Cohen et al., 1996; Thiel and Cibelli, 2002).
This methylation will prevent melanocytes to increase
fibronectin levels in response to ERK/MAP kinase signaling
and Egr-1 activation. Oncogenic transformation of melano-
cytes would then be associated with demethylation of the
fibronectin promoter. Future studies in our lab will address
the mechanism(s) through which ERK/MAP signaling upregu-
lates fibronectin in melanoma cells specifically. Whatever the
mechanism(s) involved, production of this matrix protein by
melanoma cells predicts a potential role in their transformed
phenotype.
In conclusion, our work reveals a tumor-specific regula-
tion of fibronectin by constitutive ERK/MAP kinase signaling
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and provides novel insights into the oncogenic role of B-Raf
in melanoma. Further it indicates that self-production of
fibronectin may have important implications for the biology
of melanoma progression.
MATERIALS AND METHODS
Cells, melanoma biopsies, and reagents
Human melanoma cell lines from RGP (WM35 and SBcl2), VGP
(WM793), and metastatic melanoma (1205Lu) were generously
provided by Dr M. Herlyn (Wistar Institute, Philadelphia, PA).
Primary melanomas were maintained in modified chemically
defined medium 153 with 20% Leibovitz L-15 medium, 2% fetal
bovine serum, and 5 mg/ml insulin as described previously (Satya-
moorthy et al., 2003). Human 501mel, MeWo, SK-mel28, A375, and
1205Lu melanoma cells were cultured in DMEM supplemented with
7% fetal bovine serum. The BRAF mutational status has been
determined previously (Davies et al., 2002; Satyamoorthy et al.,
2003; Tanami et al., 2004; Tsavachidou et al., 2004; unpublished
data). Human primary epidermal melanocytes were isolated from
foreskin and maintained as described previously (Bertolotto et al.,
1998). All tissue culture reagents were purchased from Invitrogen
(San Diego, CA) and Sigma Chemical Co (St Louis, MO). MEK
inhibitor U0126 was from Cell Signaling Technology (Beverly, MA).
Human recombinant HGF was obtained from PeproTech (Rocky
Hill, NJ). Melanoma biopsies were obtained from the files of the
Department of Dermatology of University Nice Hospital. The
experiments using human tissue samples were conducted according
to the Declaration of Helsinki Principles and had institutional
approval.
Immunofluorescence detection of fibronectin
Five micrometers of frozen sections of human foreskin or cutaneous
melanoma samples embedded in optimal cutting Temperature
Tissue-Tek compound were fixed in 3% paraformaldehyde in
phosphate-buffered saline for 10 minutes, and stained for fibronectin
using a rabbit polyclonal antibody (dilution, 1:400; Sigma). Sections
were also stained for the melanogenic enzyme TRP-1 using a rat
polyclonal antibody (dilution 1:20), generously provided by Dr
V. Hearing. After washing with phosphate-buffered saline, sections
were incubated with FITC-conjugated anti-rabbit and Texas Red-
conjugated anti-rat secondary antibodies (Molecular Probes, Eugene,
OR). Slides were examined with a Zeiss Axiophot fluorescence
microscope. Immunofluorescence staining of cell monolayers was
carried out as described previously (Gaggioli et al., 2005). Briefly,
cells grown on glass cover slips were fixed with 3% paraformalde-
hyde, and incubated for 1 hour with the antibody to fibronectin
diluted in phosphate-buffered saline containing 1% BSA. FITC-
coupled anti-rabbit antibody was used for detection.
DNA constructs, cell transfection, and infection
The pGL2F1900 containing the rat fibronectin gene between
positions 1908 and þ 136 fused to the luciferase reporter gene
was kindly provided by Dr I.-S. Kim and described previously (Lee
et al., 2000). A pcDNA3 vector-encoding human B-Raf was a gift
from Dr P.J. Stork. The point mutation (V600E) was generated by
site-directed mutagenesis using the Transformer kit (BD-Clontech,
San Jose, CA) and confirmed by DNA sequencing before expression.
Transfections of melanoma cells were performed according to the
lipofectamine protocol (Invitrogen). As an internal control, a LacZ-
expressing plasmid was included in each transfection. Cells were
harvested after 48 hours and luciferase activity was assessed using
the luciferase assay kit (Promega, Madison, WI). Final values were
corrected for transfection efficiency as determined by b-galactosi-
dase activity and represent means7SD from at least three
independent transfections performed in triplicates.
Adenoviral vectors for NAB2 (Ad green fluorescent protein
NAB2) and B-RafCAAX have been described previously (Ehrengru-
ber et al., 2000; Larribere et al., 2004; Gaggioli et al., 2005).
Propagation and purification of adenoviruses were performed as
described (Gaggioli et al., 2005). Adenoviruses without cDNA insert
and viruses expressing green fluorescent protein alone were used as
controls. Cells were infected at multiplicity of infection of 20 and
assayed 48 hours post-infection.
Real-time PCR
Total RNA was prepared and reverse-transcribed as described
previously (Gaggioli et al., 2005). Primer pairs for each cDNA were
designed using Primer Express Software (Applied Biosystems,
Courtaboeuf, France). Real-time PCR was performed using the
standard SYBR Green detection protocol of ABI PRISM 5700
(Applied Biosystems). Relative expression level of target genes was
normalized for RNA concentrations with four different housekeeping
genes (glyceraldehyde-3-phosphate dehydrogenase, b-actin, hypo-
xanthine-guanine phosphoribosyltransferase, and ubiquitin).
Cell lysis, immunoprecipitation, and Western blotting
Cells were solubilized in radioimmunoprecipitation assay buffer
containing 50 mM Tris (pH 7.6), 150 mM NaCl, 5 mM NaF, 2.5 mM
Na4P2O7, 1 mM Na3VO4, 0.1% SDS, 0.5% sodium deoxycholate,
and a Protease Inhibitor Cocktail (Roche Applied Science, Indiana-
polis, IN) supplemented with 1 Nonidet P-40. Lysates were then
cleared and adjusted to equal protein amounts. Proteins were
separated by SDS–PAGE, and Western blot analysis was performed
following standard protocols using the following antibodies:
fibronectin (F3648; Sigma); B-Raf (F-7; Santa Cruz Biotechnology,
Santa Cruz, CA); phospho-ERK1/2 (Thr202/Tyr204) (Cell Signaling
Technologies); Egr-1 (C-19; Santa-Cruz Biotechnology); ERK2 (D-2;
Santa Cruz Biotechnology); and transferrin receptor (TfR) (H68.4;
Zymed Laboratories Inc., San Francisco, CA). Signal was detected
using peroxydase-conjugated secondary antibody followed by
development using enhanced chemiluminescence (Amersham,
Arlington Heights, IL).
siRNA treatments
siRNAs were purchased from Eurogentec (Seraing, Belgium)
and annealing was performed as described (Elbashir et al., 2001).
Egr-1 Stealth RNAi was designed by Invitrogen. Transfection of
duplex siRNAs (200 nM) was carried out using Oligofectamine
(Invitrogen) according to the manufacturer’s protocol and resulted
in efficiencies of 490%. Cells were transfected three times in
24 hours intervals and were assayed between 92 and 96 hours
after the first transfection. The sense strand of the siRNA duplex
used to target B-Raf was 50-AgAAUUggAUCUggAUCAUTT-30
and has been described previously (Hingorani et al., 2003).
The sense strand sequence used to target human fibronectin
was 50-GUggUCCU gUCgAAgUAUU-30. As control, an siRNA
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duplex designed to target firefly luciferase transcript was used
(Harborth et al., 2001).
Cell invasion assay
The assay was carried out as described previously using the
Chemicon cell Invasion Assay kit (Chemicon International, Teme-
cula, CA) (Robert et al., 2006). Briefly, 1205Lu cells were transfected
with 200 nM of siRNA for 72 hours and serum starved overnight.
Cells were added to each well and allowed to migrate for 6 hours at
371C in 5% CO2. The lower compartment of the chamber was filled
with culture media containing 0.2% BSA. Invading cells on the
lower membrane surface were fixed in 1% paraformaldehyde,
stained with 0.1% crystal violet, and counted (five random  20
fields/well).
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